Our Story
Genabio Diagnostics Inc. is a global leader in at-home self-testing products, offering a comprehensive portfolio that includes infectious disease tests, women's health self-tests, rapid drug abuse tests, and metabolic health monitoring products.
Genabio's products are highly regarded across international markets, with established distribution channels throughout the United States, the United Kingdom, Canada, India, and Japan. Our products have captured significant market share in the U.S., making the Genabio brand widely recognized by consumers. We supply products to government agencies in New York City, LA County, Colorado, and Georgia, and continue to serve the U.S. Department of Health and Human Services. Genabio's products are trusted by prestigious hospitals, including Boston University Hospital, New York University Hospital, and the University of Kansas Hospital. Our products are available in tens of thousands of pharmacies and supermarkets, including major retailers such as Walgreens, Wegmans, H-E-B, Rite Aid, and Giant Eagle. Genabio collaborates closely with leading wholesalers, including Anda, McKesson, Medline, Cardinal, and Concordance. Furthermore, we have secured substantial orders from international diagnostic laboratories, such as Eurofins Labs and Quest Diagnostics. Notably, our COVID-19 testing products ranked second in sales among similar products on Amazon nationwide and are also sold in major retailers like Walmart and Target.
Since its founding, Genabio has surpassed $100 million in sales revenue and is currently in a phase of rapid growth. We have made strategic investments in ARCpoint Labs, which operates more than 150 branches across the United States. Genabio is advancing through initial public offerings (IPOs) and pursuing mergers and acquisitions (M&A) with high-quality technology companies globally. Our ambition is to become the world’s leading provider of self-testing solutions, delivering precise, user-friendly, and cost-effective health diagnostics to individuals worldwide within the next 5-10 years.
At Genabio Diagnostics Inc., our success in the in vitro diagnostic market is driven by cutting-edge technology, deep market expertise, and a robust network of collaborations. Looking ahead, we remain committed to innovation and excellence, with the goal of leading the global in vitro diagnostics sector.
Our mission is to enhance global health awareness and accessibility through cost-efficient, high-quality self-testing products. We strive to lead in innovation, expand our impact, and empower individuals worldwide to conveniently and accurately monitor their health.
Genabio's products are highly regarded across international markets, with established distribution channels throughout the United States, the United Kingdom, Canada, India, and Japan. Our products have captured significant market share in the U.S., making the Genabio brand widely recognized by consumers. We supply products to government agencies in New York City, LA County, Colorado, and Georgia, and continue to serve the U.S. Department of Health and Human Services. Genabio's products are trusted by prestigious hospitals, including Boston University Hospital, New York University Hospital, and the University of Kansas Hospital. Our products are available in tens of thousands of pharmacies and supermarkets, including major retailers such as Walgreens, Wegmans, H-E-B, Rite Aid, and Giant Eagle. Genabio collaborates closely with leading wholesalers, including Anda, McKesson, Medline, Cardinal, and Concordance. Furthermore, we have secured substantial orders from international diagnostic laboratories, such as Eurofins Labs and Quest Diagnostics. Notably, our COVID-19 testing products ranked second in sales among similar products on Amazon nationwide and are also sold in major retailers like Walmart and Target.
Since its founding, Genabio has surpassed $100 million in sales revenue and is currently in a phase of rapid growth. We have made strategic investments in ARCpoint Labs, which operates more than 150 branches across the United States. Genabio is advancing through initial public offerings (IPOs) and pursuing mergers and acquisitions (M&A) with high-quality technology companies globally. Our ambition is to become the world’s leading provider of self-testing solutions, delivering precise, user-friendly, and cost-effective health diagnostics to individuals worldwide within the next 5-10 years.
At Genabio Diagnostics Inc., our success in the in vitro diagnostic market is driven by cutting-edge technology, deep market expertise, and a robust network of collaborations. Looking ahead, we remain committed to innovation and excellence, with the goal of leading the global in vitro diagnostics sector.
Our mission is to enhance global health awareness and accessibility through cost-efficient, high-quality self-testing products. We strive to lead in innovation, expand our impact, and empower individuals worldwide to conveniently and accurately monitor their health.
Our Sites
We focus on connecting missing links, reacting fast to bring the most needed products and services to the labs around the world.
Global Clients
Subscription
We can help you figure out your needs.